Polar Asset Management Partners’s Intellia Therapeutics NTLA Stock Holding History

Polar Asset Management Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-32,046	Closed	-$228K	–	679
2025 Q1	$228K	Sell	32,046 -250,354	-89%	-$2.53M	0.01%	368
2024 Q4	$3.29M	Buy	282,400 +259,700	+1,144%	+$4.05M	0.04%	285
2024 Q3	$466K	Sell	22,700 -22,500	-50%	-$519K	0.01%	467
2024 Q2	$1.01M	Buy	+45,200	New	+$1.08M	0.02%	395
2022 Q3	–	Sell	-38,600	Closed	-$2M	–	1462
2022 Q2	$2M	Buy	+38,600	New	+$1.96M	0.02%	690

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Polar Asset Management Partners's NTLA Position: Q2 2025 in Review

Polar Asset Management Partners sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 32,046 shares — an estimated $228K sold.

Polar Asset Management Partners first reported a position in NTLA in Q2 2022 and held it in 5 quarters. The position peaked at $3.29M in Q4 2024. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

Polar Asset Management Partners reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
Polar Asset Management Partners sold 32,046 Intellia Therapeutics shares in Q2 2025, an estimated $228K.
Polar Asset Management Partners first reported a position in Intellia Therapeutics in Q2 2022 and held it in 5 quarters.
Polar Asset Management Partners's Intellia Therapeutics position peaked at $3.29M in Q4 2024.
280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Polar Asset Management Partners's 13F filing for Q2 2025, filed 14 Aug 2025.